Index»
inhaled
»
insulin
»
on
»
update
»
Update on Inhaled Insulin
ExuberaTM, the powdered inhalable insulin being developed by Pfizer and Sanofi-Aventis was reviewed last Thursday by the FDA’s Endocrinologic & Metabolic Drugs Advisory Committee. The committee backed the drug (and its delivery system: inhalation) as a substitute for some injections.
The FDA has yet to approve it, but often heeds recommendations of its advisory committees. FDA approval may be a year away.
ExuberaTM is the first inhalable insulin to make it this far in the route to FDA approval. Novo Nordisk (with Aradigm) and Eli Lilly (with Alkermes) also have inhalable drugs in development.
________
Pfizers press release:
FDA Advisory Committee Recommends Approval of Exubera® for Use in Adults with Type 1 and 2 Diabetes
Novo Nordisk and Aradigms press release:
Aradigm Announces Novo Nordisk Presentation of Data of AERx Insulin Diabetes Management System at the American Diabetes Association Annual Meeting
Eli Lilly and Alkermess press release:
Lilly and Alkermes Initiate Phase 3 Safety Study for Inhaled Insulin
Update on Inhaled Insulin
Tuesday, April 1, 2014
The FDA has yet to approve it, but often heeds recommendations of its advisory committees. FDA approval may be a year away.
ExuberaTM is the first inhalable insulin to make it this far in the route to FDA approval. Novo Nordisk (with Aradigm) and Eli Lilly (with Alkermes) also have inhalable drugs in development.
Pfizers press release:
FDA Advisory Committee Recommends Approval of Exubera® for Use in Adults with Type 1 and 2 Diabetes
Novo Nordisk and Aradigms press release:
Aradigm Announces Novo Nordisk Presentation of Data of AERx Insulin Diabetes Management System at the American Diabetes Association Annual Meeting
Eli Lilly and Alkermess press release:
Lilly and Alkermes Initiate Phase 3 Safety Study for Inhaled Insulin
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.